You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Durvalumab

Showing 26 - 50 of 691
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer Trial (Savolitinib, Durvalumab)

Recruiting
  • Lung Cancer
  • Beijing, China
  • +2 more
Jan 11, 2023

Nonsmall Cell Lung Cancer Stage III, Unresectable Non-Small Cell Lung Carcinoma Trial in Winston-Salem (drug, other, diagnostic

Not yet recruiting
  • Nonsmall Cell Lung Cancer Stage III
  • Unresectable Non-Small Cell Lung Carcinoma
  • Durvalumab
  • +3 more
  • Winston-Salem, North Carolina
    Wake Forest Baptist Comprehensive Cancer Center
Jan 12, 2023

Unresectable Intrahepatic Cholangiocarcinoma Trial in Baltimore (Durvalumab, SNDX-6352)

Active, not recruiting
  • Unresectable Intrahepatic Cholangiocarcinoma
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Jan 10, 2023

Premenopausal Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer Trial in Taipei City (Goserelin, Fulvestrant,

Recruiting
  • Premenopausal Breast Cancer
  • +2 more
  • Taipei City, Taiwan
    Department of Oncology, National Taiwan University Hospital
Feb 7, 2023

Urinary Bladder Tumors Trial run by the NCI (Durvalumab, Vicineum)

Recruiting
  • Urinary Bladder Neoplasms
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Feb 2, 2023

Stomach Cancer, Adenocarcinoma Trial in Seoul (Durvalumab, Savolitinib)

Recruiting
  • Stomach Cancer, Adenocarcinoma
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jan 10, 2023

Advanced Solid Tumours Trial in Beijing (Ceralasertib, Durvalumab)

Not yet recruiting
  • Advanced Solid Tumours
  • Beijing, China
    Research Site
Aug 23, 2022

Metastatic Pancreatic Cancer Trial in Barcelona, La Coruña, Santander (olaparib+durvalumab)

Recruiting
  • Metastatic Pancreatic Cancer
  • Barcelona, Spain
  • +2 more
Dec 29, 2022

Triple Negative Breast Cancer Metastatic Trial in Milano, Padova (Ceralasertib, Durvalumab, Nab-paclitaxel)

Recruiting
  • Triple Negative Breast Cancer Metastatic
  • Milano, Italy
  • +1 more
Jan 16, 2023

Bile Duct Cancer, Cholangiocarcinoma, Cholangiocarcinoma Non-resectable Trial in Boston (Gemcitabine, Cisplatin, Durvalumab)

Not yet recruiting
  • Bile Duct Cancer
  • +4 more
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
Jan 23, 2023

NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)

Not yet recruiting
  • Carcinoma, Non-Small-Cell Lung
  • Durvalumab
  • +5 more
  • (no location specified)
Aug 17, 2023

Esophagus Adenocarcinoma Trial in Frankfurt (Durvalumab, FLOT, mFOLFOX-6)

Not yet recruiting
  • Esophagus Adenocarcinoma
  • Durvalumab
  • +3 more
  • Frankfurt, Germany
    Institute of Clinical Cancer Research, University Cancer Center
Jan 26, 2023

Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Not yet recruiting
  • Hepatocellular Carcinoma
  • (no location specified)
Sep 27, 2022

Small Cell Lung Cancer Trial in Seoul (Durvalumab)

Active, not recruiting
  • Small Cell Lung Cancer
  • Durvalumab
  • Seongnam-si, Gyeonggi-do, Korea, Republic of
  • +1 more
Nov 6, 2022

EGFR-Mutated Non-Small-Cell Lung Carcinoma, Small Cell/Neuroendocrine Trial run by the National Cancer Institute (NCI)

Recruiting
  • EGFR-Mutated Non-Small-Cell Lung Carcinoma
  • Small Cell/Neuroendocrine
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,

Recruiting
  • Hepatocellular Cancer
  • +2 more
  • durvalumab
  • +4 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center
Jan 20, 2023

Small Cell Lung Cancer, Platinum-Sensitive Lung Small Cell Carcinoma, Extensive-stage Small-cell Lung Cancer Trial in Bordeaux

Not yet recruiting
  • Small Cell Lung Cancer
  • +2 more
  • Association of lurbinectedin and durvalumab
  • Association of carboplatin and etoposide
  • Bordeaux, France
    Institut Bergonié
Oct 5, 2022

Muscle Invasive Bladder Cancer Trial in Boston (Durvalumab, Oleclumab)

Completed
  • Muscle Invasive Bladder Cancer
  • Boston, Massachusetts
  • +1 more
Sep 8, 2022

Unresectable Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)

Available
  • Unresectable Hepatocellular Carcinoma
  • (no location specified)
Aug 12, 2022

NSCLC, Stage III Trial in Indianapolis (Signatera ctDNA test)

Not yet recruiting
  • NSCLC, Stage III
  • Signatera ctDNA test
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Comprehensive Cancer Ce
Mar 13, 2023

Lung Cancer, Extensive-stage Small-cell Lung Cancer, Radiotherapy Trial (Durvalumab + carboplatin/cisplatin + etoposide,

Not yet recruiting
  • Lung Cancer
  • +2 more
  • Durvalumab + carboplatin/cisplatin + etoposide
  • +2 more
  • (no location specified)
Aug 3, 2022

Head Neck Cancer Trial in Boston (Oral Decitabine, Durvalumab)

Active, not recruiting
  • Head and Neck Cancer
  • Oral Decitabine
  • Durvalumab
  • Boston, Massachusetts
    Massachusetts General Hospital
Oct 30, 2022

Recurrent Head Neck Cancer, Head Neck Cancer, Head and Neck Tumors Trial in Cincinnati (Durvalumab, Cetuximab)

Active, not recruiting
  • Recurrent Head and Neck Cancer
  • +3 more
  • Cincinnati, Ohio
    UC Health
Oct 3, 2022

Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer Trial in Edmonton (Durvalumab, Gemcitabine, Nab paclitaxel)

Not yet recruiting
  • Pancreatic Cancer
  • +3 more
  • Durvalumab
  • +5 more
  • Edmonton, Alberta, Canada
    Cross Cancer Institute
Feb 1, 2023

Breast Cancer Trial in Houston (Durvalumab, Trastuzumab, Pertuzumab)

Recruiting
  • Breast Cancer
  • Durvalumab
  • +2 more
  • Houston, Texas
    Houston Methodist Cancer Center
Aug 5, 2022